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Concise report
Components of treatment delay in rheumatoid
arthritis differ according to autoantibody status:
validation of a single-centre observation using
national audit data
Arthur G. Pratt1, Dennis Lendrem1, Ben Hargreaves1, Osman Aslam1,
James B. Galloway2 and John D. Isaacs1
Abstract
Objective. To determine whether time to treatment following symptom onset differs between RA patients
according to autoantibody status.
Methods. A single-centre retrospective analysis of a UK early RA inception cohort was first undertaken to
identify those components of the patient journey that differed by serological subtype. Data from a UK
national audit of early inflammatory arthritis patients was accessed to replicate the key finding.
Results. A total of 173 RA patients were diagnosed over a 31-month period, of whom 80 (46%) were
ACPA/RF double-seropositive (ACPA+/RF+), 53 (31%) ACPA/RF, 17 (10%) ACPA+/RF and 23 (13%)
RF+/ACPA. Overall, ACPA+/RF+ patients experienced significantly longer symptom duration before
DMARD initiation. This was accounted for by delays in their presentation to primary care following symp-
tom onset—a finding that was robustly confirmed in an independent dataset of 2192 UK early RA patients.
In contrast, ACPA/RF patients were significantly more likely to experience delays in DMARD initiation
after presenting to secondary care.
Conclusion. Causes of treatment delays in early RA differ according to patients’ autoantibody status.
More insidious symptom onset and/or distinct health-seeking behaviours among ACPA+/RF+ patients may
contribute to late presentations in primary care, whereas ACPA/RF patients experience delayed diag-
nosis and treatment in secondary care. These observations inform the research agenda, potentially influ-
encing the design of service delivery for early arthritis patients.
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Rheumatology key messages
. Following RA symptom onset, ACPA/RF double seropositivity is associated with delayed presentation to primary
care.
. Diagnostic uncertainty amongst seronegative RA patients contributes to treatment delays in secondary care.
Introduction
An established body of evidence now underlines the import-
ance of promptly treating RA with DMARDs [1]. Increasing
evidence for a window of opportunity after symptom onset,
during which therapeutic intervention meaningfully interrupts
the disease’s natural history [2, 3], supports this approach
[4, 5]. However, despite a proliferation of early arthritis
clinics intended to expedite diagnosis, patients continue to
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experience substantial and multifactorial delays between
symptom onset and treatment initiation [68].
When considering interventions to address this problem, it
has proved informative to account for those components of
the patient journey that contribute to delay. These include the
time from symptom onset to assessment in primary care,
primary care assessment to secondary care rheumatology
referral, rheumatology referral to rheumatology assessment
and rheumatology assessment to DMARD initiation [8].
Individual components of this journey have been shown
to vary markedly across healthcare infrastructures in
Europe [7], with the lag between symptom development
and primary care consultation being particularly important
in the UK [6, 9]. Intriguingly, Kumar et al. [6] provided pre-
liminary evidence that RF-positive patients tended to
endure a longer delay before primary care presentation
than their seronegative counterparts. Conversely the publi-
cation of updated classification criteria for RA [10] might
have accelerated the diagnosis of seropositive patients
due to the significance attached to autoantibodies [11].
A better understanding of how serological status may im-
pact on treatment delay in RA could influence management
guidelines in this heterogeneous disease. We have con-
ducted a retrospective analysis of a well-characterized
early RA cohort, to address whether treatment delay
varies according to serological status and, if so, which
components of the patient journey are most affected.
Methods
Newcastle patients
Consecutive patients referred to the Newcastle early
arthritis clinic (EAC) with an ultimate diagnosis of RA [12]
were eligible for inclusion in this observational study, pro-
vided they were naı¨ve to immunomodulatory therapy
(including corticosteroids) at the time of enrolment.
Primary care physicians are encouraged to refer patients
to this rapid-access service, without performing blood
tests, in all cases where a new-onset inflammatory
arthritis is suspected on clinical grounds alone, and
autoantibody results do not form part of the referral
criteria. Recruitment took place between November 2011
and November 2014, and the median duration of follow-up
from first rheumatology assessment was 17 months.
A detailed baseline clinical assessment was completed
for all patients. When available, timing of symptom onset
(as recollected by the patient) was recorded, alongside the
dates of primary care referral, EAC assessment and sub-
sequent DMARD initiation. The date of first presentation to
primary care, as recollected by the patient, was recorded
for a subgroup of the cohort. All patients provided written,
informed consent for inclusion in the study, which was
approved Newcastle and North Tyneside 2 Research
Ethics Committee (reference 12/NE/0251).
Healthcare Quality Improvement Partnership
Replication dataset
The National Clinical Audit for rheumatoid and early in-
flammatory arthritis (EIA Audit) represents one of a
number of government-funded UK audits against evi-
dence-based standards overseen by the Healthcare
Quality Improvement Partnership (HQIP). Anonymized
data collected between February 2014 and June 2015 in-
clusive were made available, following an application to
the British Society for Rheumatology Research
Committee, for the attempt to validate a key finding of
the current study. Analysis of newly referred EIA patients
was restricted to those with baseline diagnoses of RA or
undifferentiated arthritis (UA) that evolved into RA over a
3-month follow-up period, and for whom recollected
symptom duration prior to primary care presentation
was recorded. Sufficient data was also required to
permit classification according to whether or not individ-
uals were ACPA/RF double seropositive (ACPA+/RF+). All
EIA Audit data derived from The Freeman Hospital,
Newcastle, were excluded from the analysis.
Statistical analysis
Differences in continuous and categorical variables be-
tween comparator groups were determined using the
KruskalWallis/MannWhitney U and chi-squared tests, re-
spectively, with significance set at a = 5%. To determine
and visualize differences in time components between
symptom onset and DMARD initiation according to
serotype, time-to-event data were analysed using
KaplanMeier survival plots; differences between serotypes
were tested using the MantelCox log-rank method or Cox
regression modelling when adjusting for covariates (likeli-
hood ratio test). A total of 173 consecutively diagnosed RA
patients contributed to the final Newcastle dataset,
although component time points were missing for some
individuals (as stipulated in Table 1). A sensitivity analysis
of a subcohort of 144 patients, in whom53 time compo-
nents were available, gave similar results to the complete
cohort (compare Table 1 with supplementary Table S1,
available at Rheumatology Online). The same analysis ap-
proach was applied to the HQIP replication cohort.
Results
Newcastle patient characteristics
The clinical characteristics of the complete Newcastle
cohort are described in Table 1, stratified by autoantibody
serotype. Of this cohort, 80 (46%) were ACPA and RF
double-seropositive (ACPA+/RF+), 53 (31%) were ACPA
and RF double-seronegative (ACPA/RF), 17 (10%)
were ACPA+/RF and 23 (13%) were ACPA/RF+. A ten-
dency for ACPA+/RF+ RA patients to be younger achieved
marginal significance (P = 0.05). A trend towards lower
disease activity at baseline was also observed in this
group and, conversely, ACPA/RF individuals appeared
enriched for males (both non-significant). No significant
differences in NSAID use were observed between the
four groups, with 60% of patients reporting usage at en-
rolment. The durations of the various components of the
patient journey are also listed in Table 1. Out of the overall
cohort of 173 patients, 24 evolved diagnoses of RA during
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the course of follow-up in secondary care, having initially
presented with UA.
ACPA/RF seropositivity predicts prolonged symptom
duration before primary care referral
The median time between symptom onset and DMARD
initiation was 17 weeks for the complete cohort (data
available for 167 patients). However, clear differences
were seen in time-to-treatment when patients were stra-
tified by autoantibody serotype, with ACPA+/
RF+ individuals experiencing the longest delays (P
= 0.006) (Table 1 and Fig. 1A). Given the trend towards
lower acute phase response and DAS28 in the ACPA+/
RF+ group, and to exclude a confounding effect of these
variables in our primary analysis, Cox regression con-
firmed that serotype remained associated with treatment
delay independently of these two parameters (P = 0.028).
As depicted in Fig. 1B, the relative delay in treatment ini-
tiation among ACPA+/RF+ patients was fully accounted for
by the time between symptom-onset and primary care
referral date; neither time between primary care referral
and EAC consultation in secondary care, nor time be-
tween EAC consultation and DMARD initiation, contribu-
ted to the difference (Table 1). Interestingly, analysis of a
subcohort of 43 patients for whom the date of first primary
care consultation was available demonstrated that treat-
ment delays for ACPA+/RF+ RA patients resulted from pa-
tient rather than primary care factors—specifically a delay
in the patient’s presentation to primary care following
symptom onset (Fig. 1C)—and not in the primary care
physician’s decision to refer (Table 1).
Validation of single-centre observation using national
audit data
Although not without precedent [6], the finding that
ACPA+/RF+ RA patients present to primary care with pro-
tracted symptom duration appeared counterintuitive, con-
sidering established evidence for this being the more
aggressive disease subset. We therefore sought to valid-
ate our observation using appropriate national audit data.
The independent EIA dataset comprised 4334 individuals
diagnosed at baseline with RA or UA evolving into RA,
from a total of 169 secondary care UK rheumatology
units. Among these, sufficient data were available for
only 2192 individuals (51%). ACPA+/RF+ patients were
significantly younger than comparator RA patients in this
cohort, whose characteristics are summarized in supple-
mentary Table S2, available at Rheumatology Online. As in
the Newcastle cohort, ACPA+/RF+ patients were symp-
tomatic for longer than patients seronegative for one or
more autoantibodies prior to their first primary care con-
sultation, providing a robust validation of our single-centre
observation (P< 0.001; Fig. 1D)—a finding that was robust
to incorporation of age as a covariate. Interestingly, in
contrast, analysis of the HQIP replication cohort revealed
that RA patients were subsequently referred by their pri-
mary care physician significantly more quickly if they were
ACPA+/RF+—and this largely reversed any overall delay
between symptom onset and primary care referral
TABLE 1 Characteristics of RA patients, stratified by serotype
Characteristics
RA patients
n=173
Double
seropositive
(n = 80)
ACPA+/RF
(n = 17)
RF+/ACPA
(n = 23)
Double
seronegative
(n =53) P-valuea
Age, yearsb 58 (4971) 63 (4871) 65 (5074) 68 (5775) 0.050
Female sex, %b 67 82 73 58 0.244
CRP, g/dlb 9 (522) 10 (716) 17 (1138) 14 (627) 0.090
ESR, mm/minb 23 (1135) 27 (1732) 35 (1449) 23 (934) 0.387
SJC/68b 2 (15) 2 (14) 4 (07) 3 (17) 0.081
TJC/68b 4 (18) 3 (15) 5 (211) 5 (211) 0.103
DAS28b 4.26 (2.795.33) 4.28 (3.194.88) 5.03 (4.185.70) 4.41 (3.785.35) 0.161
Symptoms-DMARD, weeks, n = 167c 24 (10 to>52) 13 (6 to >52) 9 (615) 17 (1030) 0.006
Symptoms-PC Referral, weeks, n = 144c 15 (644) 7 (419) 6 (211) 9 (519) 0.012
Symptoms—first PC visit, weeks, n = 43c 14 (437) 4 (225) 2 (0.513) 4 (027) 0.036
First GP visit—PC Referral, weeks, n = 43 c 1 (010) 2 (06) 3 (04) 4 (012) 0.989
PC Referral-EAC, weeks, n = 154c 3 (24) 3 (14) 3 (23) 2 (24) 0.924
EAC-DMARD, weeks, n = 173c 0 (02) 0 (03) 0 (01) 1 (08) 0.005
All values given as median (interquartile range) unless otherwise indicated. P <0.05 are highlighted in boldface.
aKruskallWallis (non-parametric analysis of variance) for continuous variables; Chi-squared test for sex. bClinical character-
istics are shown for all patients at the time of presentation to the Early Arthritis Clinic (EAC). cIndicated time periods are shown
for subgroups of patients for which data is available (number indicated by n). SJC/68: swollen joint count out of 68 joints and
TJC/68: tender joint count out of 68 joints; DAS28 (28 joints, ESR); PC: primary care.
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observed between groups (supplementary Table S2,
available at Rheumatology Online).
Seronegative RA patients are subject to delayed
DMARD initiation once in secondary care
After assessment by a consultant rheumatologist, most
RA patients were commenced on one or more DMARDs
immediately, but significant delays of a month or more
occurred in 35 (20%) cases, ranging up to 56 weeks in
duration. ACPA/RF patients experienced a consistently
prolonged time-to-treatment following secondary care as-
sessment, compared with counterparts who were sero-
positive (Fig. 1E), and they were more likely to
experience delays of 51 month before DMARD initiation
FIG. 1 Components of treatment delay in early RA patients differ according to serological status
(A) KaplanMeier plot depicting patient survival, symptom onset to DMARD initiation, stratified by autoantibody double-
seropositivity. (B) Analogous plot to A, symptom onset to general practitioner (GP) referral. (C) KaplanMeier plot for
subcohort of patients with available data, depicting survival, symptom onset to first GP visit. (D) KaplanMeier plot
analogous to C, pertaining to Healthcare Quality Improvement Partnership replication cohort. (E) Survival from first EA
clinic consultation to DMARD initiation, stratified by autoantibody double-seronegativity. (F) Bar chart contrasting pro-
portions of double seronegative RA patients according to whether they encountered treatment delays in secondary care.
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(P = 0.018, chi-squared test; Fig. 1F). Diagnostic delay ap-
peared to be an important contributor, with a significantly
higher proportion of ACPA/RF patients initially present-
ing with UA (19 of 53; 36%), compared with patients sero-
positive for either antibody (5 of 120, 4%; P< 0.001, Chi-
squared test).
Discussion
Some important observations arise from our work. First
and foremost, ACPA/RF double seropositivity appears to
be a risk factor for delayed presentation of early RA pa-
tients to primary care following symptom onset. We have
replicated our single-centre observation using a large na-
tional clinical audit dataset, providing an early example of
the HQIP EIA resource’s value as a research tool. In
Newcastle, delayed presentation to primary care ac-
counted for overall delays in DMARD initiation in ACPA+/
RF+ RA patients compared with those of other serotypes.
Given the importance of prompt therapeutic intervention
in the condition, which is arguably even more urgent in
seropositive disease, this observation may have important
prognostic implications. A more insidious symptom
course among double-seropositive RA patients is sug-
gested by our data, and continued efforts to define symp-
tom and health-seeking behaviour patterns in this
apparently younger group are prescient [13]. Further stu-
dies, employing qualitative approaches and/or prospect-
ive designs, are now needed to properly understand the
phenomenon, and the extent to which it is replicated
across healthcare systems remains to be determined.
Taken together, however, our validated observation
adds credence to the notion that autoantibody status de-
fines pathophysiologically distinct, if overlapping, disease
phenotypes [14]. The finding may also have implications
for clinical service provision, potentially supporting readier
access to ACPA screening in the community.
However, such an approach needs to be balanced
against the risk that autoantibody seronegativity may pro-
vide false reassurance to primary care physicians when
considering referral of patients with possible RA to sec-
ondary care. Although not altogether conclusive, contrast-
ing data from the Newcastle and HQIP replication cohorts
seem to illustrate this point: while delays between primary
care presentation and referral were equivalent between
ACPA+/RF+ patients and those of other serotypes in
Newcastle (where pre-referral blood tests are discour-
aged), delays were significantly longer for RA patients
with one or more negative autoantibodies in the national
cohort, in which specific referral pathways and practices
vary greatly. It is therefore conceivable that channelling by
autoantibody serotype prior to referral occurred preferen-
tially in the replication cohort. Mapping optimal practice in
the light of such observations presents an important chal-
lenge for future studies.
Finally, our study has highlighted the ongoing clinical
challenge that rheumatologists face in diagnosing sero-
negative RA, despite the advent of classification criteria
developed specifically for use in early disease. UA was
more frequently diagnosed in this group, which was also
uniquely subject to delays in DMARD initiation after pres-
entation to consultant rheumatologists in secondary care.
Interventions that aid in this process, in the form of diag-
nostic biomarkers that reflect disease-specific immune
dysregulation, are the subject of ongoing investigation
[12, 15].
Our single-centre study was large and utilized an un-
selected, real-life RA patient cohort; no evidence was
found for bias as a result of missing data (see Methods;
Statistical analysis section). The generalizability of its find-
ings was tested against a UK replication cohort, placing
them in a national context. Analysis of the HQIP replica-
tion cohort was hampered by substantial missing data,
likely reflecting the organizational challenge of collecting
complex datasets at the level of individual rheumatology
units—and this cannot be excluded as a source of bias.
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